Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
|Articles|June 28, 2012
Schizophrenia Pharmacotherapy: What Role for Perphenazine? (Video 1:39 minutes)
Author(s)Peter F. Buckley, MD
Listen
0:00 / 0:00
Key Takeaways
- Positioning perphenazine as an evidence-based maintenance alternative is reasonable for patients stable on FGAs or needing a lower-cost option, while individualizing risk–benefit versus SGAs.
- CATIE data showed similar discontinuation and symptom outcomes versus several atypicals, undermining assumptions of universal SGA superiority and highlighting adherence, comorbidity, and side-effect burden as key determinants.
In schizophrenia therapy, perphenazine can play in combating symptoms and in preventing relapse, though it can be associated with metabolic side effects.
Advertisement
In schizophrenia therapy, perphenazine can play in combating symptoms and in preventing relapse, though it can be associated with metabolic side effects.
Perphenazine was used in the CATIE study. Here, Dr. Peter Buckley addresses:
• The current role of perphenazine in the management of schizophrenia.
• The drug’s association with weight gain.
• The metabolic side effect profile of perphenazine.
Advertisement
Related to this article
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Evidence-Based Ethical Principles for Long-Acting Injectable Antipsychotic Use
2
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
3
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5